Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1d4f91ec253d18f8f1567944da556c3 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2017-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd112c071e77825f5ab5ba6466927b4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9794a43c7960b1a518a7a28afd93e9d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c581f9b83d1d2afe74762a7aff102c3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_271b86f64487b703efac74ed8148d493 |
publicationDate |
2017-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9834594-B2 |
titleOfInvention |
Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
abstract |
The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10703802-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016052997-A1 |
priorityDate |
2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |